Alibaba's first-quarter net profit attributable to shareholders drops 75.56% year-on-year, while AI-related product revenue achieves triple-digit growth for the twelfth consecutive quarter

Stock News
Aug 21

Hengrui Medicine (01276): The SHR-7012 injection, intended for the treatment of cutaneous lupus erythematosus, has been approved for clinical trials.

Wuyi Horizon (06651) has established a joint venture with United Imaging to launch AperData, an embodied intelligence data platform.

CanSino Biologics (06185): The tetanus vaccine has received NDA approval from the National Medical Products Administration.

Beijing Energy International (00686): A subsidiary plans to invest 236 million yuan in the comprehensive energy socialized investment cooperation project at Beijing University of Technology.

In terms of operational performance, BABA-W (09988) reported a 75.56% year-on-year decline in first-quarter net profit attributable to shareholders, while AI-related product revenue continued to see triple-digit growth for the twelfth consecutive quarter.

Ping An Insurance (02318) released its interim results, with net profit attributable to shareholders reaching 92.585 billion yuan, up 36.06% year-on-year.

NetEase (09999) achieved net revenue of approximately 60.7 billion yuan in the first half of the year, up 7.0% year-on-year, with long-term game operations and new product pipelines supporting sustained development.

China Telecom (00728) posted interim results with profit attributable to shareholders of 19.588 billion yuan, down 14.9% year-on-year.

CITIC Securities (06030) reported interim results with net profit attributable to shareholders of 23.343 billion yuan, up 69.6% year-on-year.

Pop Mart (09992) released interim results with profit attributable to shareholders of 5.038 billion yuan, up 10.1% year-on-year, as plush product revenue sustained strong growth momentum.

Henderson Land Development (00012) posted interim results with profit attributable to shareholders of HK$4.09 billion, up 40.65% year-on-year.

China Tourism Group Duty Free (01880) announced interim results with profit attributable to equity shareholders of approximately 3.134 billion yuan, up 19.52% year-on-year.

J&T Express-W (01519) released interim results with adjusted net profit of US$351 million, up 124.3% year-on-year.

BOC Aviation (02588) posted interim results with after-tax net profit of US$357 million, up 4% year-on-year.

Li Ning (02331) announced interim results with net profit attributable to equity holders of 1.816 billion yuan, up 4.53% year-on-year.

3SBio (01530) released interim results with profit attributable to shareholders of 1.147 billion yuan, down 15.58% year-on-year.

Simeere Pharmaceutical (02096) announced interim results with adjusted net profit of approximately 964 million yuan, up 48.7% year-on-year.

Cloud Music (09899) reported interim results with revenue of approximately 3.959 billion yuan, up 3.4% year-on-year.

Dongyue Group (00189) released interim results with profit attributable to shareholders of 1.027 billion yuan for the period, up 31.84% year-on-year.

Blue Moon Group (06993) released interim results with revenue of HK$2.883 billion, reflecting steadily improving operational efficiency.

Hua Medicine-B (02552) posted interim results with revenue up 74% year-on-year to 378.9 million yuan, as its self-commercialization strategy proves effective.

Zhou Hei Ya (01458) saw first-half revenue grow 19.5% year-on-year to 1.461 billion yuan, with channel business experiencing rapid growth as the company expands into compound seasoning and overseas markets.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10